Compare RYTM & HLNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RYTM | HLNE |
|---|---|---|
| Founded | 2008 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.4B |
| IPO Year | 2017 | 2017 |
| Metric | RYTM | HLNE |
|---|---|---|
| Price | $112.03 | $128.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 9 |
| Target Price | $125.77 | ★ $160.56 |
| AVG Volume (30 Days) | ★ 887.7K | 505.9K |
| Earning Date | 11-04-2025 | 02-03-2026 |
| Dividend Yield | N/A | ★ 1.66% |
| EPS Growth | N/A | ★ 19.80 |
| EPS | N/A | ★ 5.55 |
| Revenue | $174,334,000.00 | ★ $733,070,000.00 |
| Revenue This Year | $47.34 | $8.42 |
| Revenue Next Year | $57.18 | $19.65 |
| P/E Ratio | ★ N/A | $23.48 |
| Revenue Growth | ★ 54.92 | 13.01 |
| 52 Week Low | $45.91 | $111.98 |
| 52 Week High | $122.20 | $179.19 |
| Indicator | RYTM | HLNE |
|---|---|---|
| Relative Strength Index (RSI) | 57.51 | 54.23 |
| Support Level | $109.59 | $121.55 |
| Resistance Level | $122.20 | $135.56 |
| Average True Range (ATR) | 5.23 | 4.25 |
| MACD | 1.04 | 0.84 |
| Stochastic Oscillator | 54.25 | 56.94 |
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
Hamilton Lane Inc is a private markets investment firm globally, providing solutions to institutional and private wealth investors around the world. Dedicated exclusively to private markets investing for more than 30 years, the firm currently employs approximately 750 professionals operating in offices throughout North America, Europe, Asia Pacific, and the Middle East. It has approximately $986 billion in assets under management and supervision, composed of nearly $141 billion in discretionary assets and more than $845 billion in non-discretionary assets. The group specializes in building flexible investment programs that provide clients access to the full spectrum of private markets strategies, sectors, and geographies.